Eli Lilly shares slip 7% premarket as weight-loss pill study overshadows earnings
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
Morgan Stanley Reiterates Overweight Rating on Eli Lilly (LLY)
August 8, 2025 7:10 AM EDTMorgan Stanley analyst Terence Flynn reiterated an Overweight rating and $1,135.00 price target on Eli Lilly (NYSE: LLY)
The analyst comments "We believe we are at an inflection point for "The Broadening" of GLP-1 use, which will extend beyond US-based early adopters to... More
